



Contents

Editorial

- 429 Editorial
Uziel Beller, MD

Basic Science

- 430 Aberrant Expression of the Von Hippel-Lindau Gene in Human Endometrial Hyperplasia and Endometrial Carcinoma
Jian-Ying Xu, MSc, Wei-Jie Zhu, PhD, Xiao-Zhe Cao, PhD, Xian-Feng Li, BSc, and Jin Wu, BSc
- 435 Changes in Activities of Caspase-8 and Caspase-9 in Human Cervical Malignancy
Maria Themistokli Ekonomopoulou, PhD, Evaggelos Babas, PhD, Eleutheria Mioglou-Kalouptsi, PhD, Maria Malandri, MD, and Zafroula Iakovidou-Kritsi, PhD
- 439 Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells With Acquired Paclitaxel Resistance
Yunfeng Fu, PhD, Dongxiao Hu, MD, Jian Qiu, MD, Xing Xie, MD, Feng Ye, PhD, and Wei-Guo Lu, PhD
- 445 P21 Ser31Arg Polymorphism and Cervical Cancer Risk: A Meta-Analysis
Ya Li, MD, Fei Liu, MD, Shiqiao Tan, MD, and Shangwei Li, MD

(continued next page)

Contents *(continued)*

- 452 *P16* Methylation Is an Early Event in Cervical Carcinogenesis
Lee-Wen Huang, MD, Hun-Shan Pan, MD, Yu-Hung Lin, MD, Kok-Min Seow, PhD, Heng-Ju Chen, MD, and Jiann-Loung Hwang, MD

- SDC** 457 Functional Characterization of a Fluorescent Highly Tumorigenic Ovarian Cancer Line to Test Cellular Therapy in Experimental Models
Susan Blaydes Ingersoll, PhD, Sarfraz Ahmad, PhD, Gregory P. Stoltzfus, MS, Sheylan Patel, BS, Michael J. Radi, MD, Neil J. Finkler, MD, John R. Edwards, MD, and Robert W. Holloway, MD

Ovarian Cancer

- 466 Squamous Cell Carcinoma Arising From Mature Cystic Teratoma of the Ovary
An-Jen Chiang, MD, Victor La, BS, Jiaqi Peng, BS, Ken-Jen Yu, MD, PhD, and Nelson N.H. Teng, MD, PhD
- 475 Clinical Characteristics of Patients With Prolonged Disease-Free Survival After Primary Treatment in Advanced Ovarian Cancer: A Brief Report
Michael R. Milam, MD, MPH, Robyn Harrell, MS, Roland Bassett, MS, Lynn P. Parker, MD, Daniel S. Metzinger, MD, and Pedro T. Ramirez, MD
- 478 Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer: A Phase Ib Study
Guillermo Crespo, PhD, Marta Sierra, PhD, Raquel Losa, PhD, José Pablo Berros, MD, Noemí Villanueva, MD, Joaquín Fra, MD, Paula J. Fonseca, PhD, María Luque, MD, Yolanda Fernández, MD, Pilar Blay, PhD, Miguel Sanmamed, MD, Carolina Muriel, PhD, Emilio Esteban, PhD, and Ángel J. Lacave, PhD
- 486 Loss/Down-Regulation of Tumor Suppressor in Lung Cancer 1 Expression Is Associated With Tumor Progression and Is a Biomarker of Poor Prognosis in Ovarian Carcinoma
Guofen Yang, MD, Weipeng He, MD, Muyan Cai, MD, Fei Luo, MD, Hsiangfu Kung, PhD, Xinyuan Guan, PhD, Yixin Zeng, MD, PhD, and Dan Xie, MD, PhD

Uterine Cancer

- 494 Consistency of In Vitro Chemoresponse Assay Results and Population Clinical Response Rates Among Women With Endometrial Carcinoma
Warner K. Huh, MD, Michael Cibull, MD, Holly H. Gallion, MD, Christine M. Gan, PhD, Scott Richard, MD, and David E. Cohn, MD

(continued next page)

Contents *(continued)*

- 500 Estimating the Risk of Endometrial Cancer in Symptomatic Postmenopausal Women: A Novel Clinical Prediction Model Based on Patients' Characteristics
Nikolaos Burbos, MRCOG, Patrick Musonda, PhD, Timothy J. Duncan, MRCOG, Simon G. Crocker, FRCOG, Edward P. Morris, FRCOG, and Joaquin J. Nieto, FRCOG
- 507 Is Lymphadenectomy Justified in Endometrial Cancer?
Johannes Dietl, MD, PhD
- 511 The Revised 2009 FIGO Staging System for Endometrial Cancer: Should the 1988 FIGO Stages IA and IB Be Altered?
Nadeem R. Abu-Rustum, MD, Qin Zhou, PhD, Alexia Iasonos, PhD, Kaled M. Alektiar, MD, Mario M. Leitao Jr, MD, Dennis S. Chi, MD, Yukio Sonoda, MD, Robert Soslow, MD, Martee Hensley, MD, and Richard R. Barakat, MD
- 517 A Phase II Trial of Paclitaxel and Carboplatin in Women With Advanced or Recurrent Uterine Carcinosarcoma
Robin A. Lacour, MD, MPH, Elizabeth Euscher, MD, E. Neely Atkinson, PhD, Charlotte C. Sun, MPH, DrPH, BA, Pedro T. Ramirez, MD, Robert L. Coleman, MD, Jubilee Brown, MD, Jacalyn B. Gano, MSW, BS, AS, Thomas W. Burke, MD, and Lois Michelle Ramondetta, MD
- 523 Activated Leukocyte Cell Adhesion Molecule Expression Is Up-Regulated in the Development of Endometrioid Carcinoma
Shumei Liang, PhD, Cuiping Huang, PhD, Shuangzheng Jia, MD, and Bo Wang, MD, PhD
- 529 Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma
Divya Gupta, MD, Marc J. Gunter, PhD, Kathleen Yang, MD, Stephen Lee, MD, Lisa Zuckerwise, MD, Lee-may Chen, MD, Gary L. Goldberg, MD, and Gloria S. Huang, MD

Cervical Cancer

- 535 Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer: Mature Results of the Phase 2 PBM-PFU Protocol
Rebecca McCaffrey, MD, Mert Bahtiyar, MD, Ernest I. Kohorn, MD, Joseph T. Chambers, PhD, MD, Peter E. Schwartz, MD, and Setsuko K. Chambers, MD

(continued next page)

Contents *(continued)*

- 545 Molecular Methods for a Correct Diagnosis of Multiple HPV Infections and Clinical Implications for Vaccine

Andrea Tinelli, MD, Giuseppe Leo, PhD, Domenico Dell'Edera, MD, Fabio Storelli, PhD, Maria Maddalena Galante, PhD, Marcello Guido, PhD, Gernot Hudelist, MD, PhD, and Antonio Malvasi, MD

- 551 Genetic Diversity of HPV-16 E6, E7, and L1 Genes in Women With Cervical Lesions in Liaoning Province, China

Zhengrong Sun, PhD, Gaowei Ren, BS, Xin Cui, BS, Weiqiang Zhou, BS, Chao Liu, BS, and Qiang Ruan, MD

Vulvar Cancer

- 559 A Prospective Study of Sentinel Lymph Node Detection in Vulval Carcinoma: Is It Time for a Change in Clinical Practice?

Omer Devaja, PhD, MRCOG, Gautam Mehra, MRCOG, Michael Coutts, MAFRCPath, FRCPA, Sebastian Adamson, MBBS, Steven Attard Montalto, MRCOG, John Donaldson, MA, MRCS, LRCP, FRCR, and Andreas J. Papadopoulos, MD, MRCOG

Surgeon's Corner

- 565 Vertical Rectus Abdominis Musculocutaneous Flap: A Good Option for Reconstruction of Large Inguinofemoral Defects With Exposure of the Femoral Vessels: Brief Report Focusing on Management of Advanced Vulvar Carcinoma

Ricardo Horta, MD, Rita Filipe, MD, Joana Costa, MD, Pedro Silva, MD, José Amarante, PhD, and Álvaro Silva, MD

- 568 Ovarian Sentinel Node: Is It Feasible?

Reita H. Nyberg, MD, Pasi Korkola, Lic Tech, MD, PhD, and Johanna Mäenpää

Quality of Life

- 573 Religious and Spiritual Beliefs of Gynecologic Oncologists May Influence Medical Decision Making

Lois Ramondetta, MD, Alaina Brown, MD, Gwyn Richardson, MD, Diana Urbauer, MS, Premal H. Thaker, MD, Harold G. Koenig, MD, Jacalyn B. Gano, MSW, and Charlotte Sun, DrPH

(continued next page)

Contents *(continued)*

582 Lower Extremity Glandography (LEG): A New Concept to Identify and Enhance Lymphatic Preservation

Alexander F. Burnett, MD, Pamela J.B. Stone, MD, Suzanne V. Klimberg, MD, Jennifer L. Gregory, MD, and Juan R. Roman, MD

587 Complementary and Alternative Medicine Use Among Women Receiving Chemotherapy for Ovarian Cancer in 2 Patient Populations

Limor Helpman, MD, Sarah E. Ferguson, MD, Melanie Mackean, MD, Amira Rana, MD, Lisa Le, MSc, Morven A. Atkinson, RN, Andrew Rogerson, MD, and Helen Mackay, MD

Listed in *Current Contents/Clinical Medicine, Science Citation Index Expanded (SCIE), Journal Citation Reports/Science Edition, and MEDLINE.*

Subscription Prices: Annual subscription prices worldwide: \$746.40 Individual Domestic, \$910.40 Individual International, \$1,663.40 Institutional Domestic, \$1,881.40 Institutional International, \$452.40 Resident Domestic, \$452.40 Resident International. (The Canadian GST Tax of 7% will be added to the subscription price of all orders shipped to Canada. Lippincott Williams & Wilkins' GST Identification Number is 895524239. Publications Mail Agreement #40052291.) Subscriptions outside the United States must be prepaid. All prices include a handling charge. Subscriptions outside of North America include \$14 for air freight delivery. Price subject to change without notice. Copies will be replaced without charge if the publisher receives a request within 90 days of the mailing date, both in the U.S. and worldwide. Visit us on-line at www.lww.com.

Institutional rates are for print only; online subscriptions are available via Ovid. Institutions can choose to purchase a print and online subscription together for a discounted rate. Institutions that wish to purchase a print subscription, please contact Lippincott Williams & Wilkins, 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116; phone 1-800-638-3030 (outside the United States 301-223-2300); fax 301-223-2400. Institutions that wish to purchase an online subscription or online with print, please contact the Ovid Regional Sales Office near you or visit www.ovid.com/site/index.jsp and select Contact and Locations.

Copyright and Permission: Materials in The International Journal of Gynecological Cancer are covered by copyright. Copyright © 2011 IGCS and ESGO. Permission to photocopy must be secured in writing from: Permissions Dept., Lippincott Williams & Wilkins, Inc., 351 West Camden Street, Baltimore, MD 21201, Fax: 410-528-8550; or the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, Telephone: 978-750-8400, Fax: 978-646-8600, E-mail: info@copyright.com.

Commercial reprints: Reprints of individual articles are available from authors. In addition, articles are available to be downloaded from the journal Web site, <http://www.ijgc.net>, without charge by subscribers and for a fee by nonsubscribers. Quantities of reprints greater than 100 for commercial or academic use may be purchased from Lippincott Williams & Wilkins. For information and prices, contact Kimberly Chek at 410-528-4227; E-mail: Kimberly.Chek@wolterskluwer.com.

Disclaimer: The statements and opinions contained in the articles of The International Journal of Gynecological Cancer are solely those of the individual authors and contributors and not those of the IGCS, the ESGO, or Lippincott Williams & Wilkins. The appearance of advertisements in the Journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The IGCS, the ESGO, and the Publisher disclaim responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

POSTMASTER: Send address changes to International Journal of Gynecological Cancer, P.O. Box 1550, Hagerstown, MD 21740.